GlobeNewswire

Austria introduces nationwide standard of clinical terminology with membership in SNOMED International

Share

London, United Kingdom, March 06, 2019 (GLOBE NEWSWIRE) -- Austria through ELGA GmbH, “elektronische Gesundheitsakte”, and SNOMED International jointly announce the addition of Austria as the organization’s thirty-seventh Member.

With its continued development, Austria’s ELGA electronic health record system enables all eligible users including citizens, patients, physicians, nurses, pharmacists, etc. to gain access to healthcare information. When it comes to establishing and operating a nationwide personal health record, effective and efficient terminology management including the development, administration, maintenance and publishing of clinical terminology is truly a precondition to achieving semantic interoperability. Further, within the European region, the promise of cross-border care and clinical information mobility is believed to be the single most important revolution in healthcare. The role that structured data plays in supporting this vision is critical.

SNOMED CT is the world’s most comprehensive and precise health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. “SNOMED CT is a core element in building a platform for accurate clinical information exchange and data analysis” states SNOMED International’s CEO, Don Sweete. “We welcome Austria’s membership in the organization and look forward to a future where SNOMED CT’s structured terminology supports the goal of a clinically networked nation for Austria.”

The ELGA GmbH program has been in place since 2009 and is financed by the Austrian Republic, Austria’s 9 Federal States and the Social Insurance Group. Mandated with managing the technical and organizational implementation of its national electronic health record, ELGA recognizes that semantic interoperability within a nationwide electronic patient record can only be achieved by providing standardized terminologies. In order to appropriately address clinical documentation, a plethora of special terms, abbreviations and codes, organized in systems like nomenclatures and classifications is a prerequisite.

Dr. Stefan Sabutsch, Head of the SNOMED Release Center Austria and Executive Lead Standards & Usability at ELGA GmbH, emphasizes: "With the introduction of SNOMED CT in Austria, we have taken a further important step in in the field of information and communication technologies in the healthcare sector. Confessing to a nationwide standard of clinical terminology as an integrative part of the Austrian Health Record ELGA shows clearly that the responsible people in the country are absolutely committed to the importance of semantic interoperability.” Sabutsch adds "a clinically validated terminology such as SNOMED CT has great relevance to the Austrian healthcare system and will play a key role in improving the efficiency and quality of the existing healthcare system and benefiting the patients."

Austria becomes the 24th Member from Europe, the Middle East and Africa to join SNOMED International, laying the groundwork for increased interoperability across the region. SNOMED CT becomes part of Austria’s national infrastructure as a contributor ensuring the exchange of accurate, relevant and timely information across needed ELGA provider and consumer health information systems.

Click here to learn more about Austria’s membership in SNOMED International.

About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Visit the SNOMED International website to learn more.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CESTPress release

Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April

Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CESTPress release

Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have